Melatonin as a potential modulator of Nrf2

被引:106
|
作者
Ahmadi, Zahra [1 ]
Ashrafizadeh, Milad [2 ]
机构
[1] Islamic Azad Univ, Shoushtar Branch, Dept Basic Sci, Shoushtar 5563584, Iran
[2] Univ Tabriz, Fac Vet Med, Dept Basic Sci, Tabriz 1455742, Iran
关键词
Antioxidant response element; Cancer therapy; Melatonin; Nrf2 signaling pathway; Oxidative stress; NF-KAPPA-B; EARLY BRAIN-INJURY; OXIDATIVE STRESS; SIGNALING PATHWAY; ACTIVATION; PROTECTS; EXPRESSION; NEUROINFLAMMATION; APOPTOSIS; DRUGS;
D O I
10.1111/fcp.12498
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nuclear factor erythroid 2-related factor 2 (Nrf2) is considered as the sensor of oxidative stress, and the main aim of this signaling pathway is to maintain physiological condition by induction of redox balance. Also, this pathway exerts anti-inflammatory effects via antioxidant response element. Oxidative stress is a key factor in a variety of pathological conditions and high level of oxidative stress is associated with damages in lipids, proteins, genetic material, and cell membrane. Multiple drugs have been developed in order to diminish oxidative stress. However, synthetic drugs suffer from various drawbacks such as high cost and side effects. On the other hand, naturally occurring compounds are of interest due to their minimal side effects and valuable biological activities. Melatonin is a hormone of pineal gland which is found in different plants. This compound has a variety of favorable biological and therapeutic activities such as antioxidant, anti-inflammatory, anti-tumor, anti-diabetic, and cardioprotection. At the present review, we demonstrate that Nrf2 signaling pathway explains some of the therapeutic and biological effects of melatonin.
引用
收藏
页码:11 / 19
页数:9
相关论文
共 50 条
  • [11] Melatonin Activates NRF2 and Autophagy in Human Placental Trophoblasts.
    Sagrillo-Fagundes, Lucas
    Bienvenue-Pariseault, Josianne
    Vallancourt, Cathy
    REPRODUCTIVE SCIENCES, 2016, 23 : 236A - 237A
  • [12] Nrf2 is a critical modulator of the innate immune response in a model of uveitis
    Nagai, Norihiro
    Thimmulappa, Rajesh K.
    Cano, Marisol
    Fujihara, Masashi
    Izumi-Nagai, Kanako
    Kong, Xiaoni
    Sporn, Michael B.
    Kensler, Thomas W.
    Biswal, Shyam
    Handa, James T.
    FREE RADICAL BIOLOGY AND MEDICINE, 2009, 47 (03) : 300 - 306
  • [13] Identification of NRF2 target genes in human cells: Aldoketo reductases as a potential biomarker for NRF2 activity
    Choi, Bo-hyun
    Jung, Kyeong-Ah
    Song, Mingu
    Kwak, Mi-Kyoung
    CANCER RESEARCH, 2012, 72
  • [14] Potential Applications of NRF2 Inhibitors in Cancer Therapy
    Panieri, Emiliano
    Saso, Luciano
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2019, 2019
  • [15] Nrf2: a potential therapeutic target for diabetic neuropathy
    Anil Kumar
    Ruchika Mittal
    Inflammopharmacology, 2017, 25 : 393 - 402
  • [16] The untapped potential of targeting NRF2 in neurodegenerative disease
    Chen, Wei-Tai
    Dodson, Matthew
    FRONTIERS IN AGING, 2023, 4
  • [17] The molecular biology and therapeutic potential of Nrf2 in leukemia
    Khodakarami, Atefeh
    Adibfar, Sara
    Karpisheh, Vahid
    Abolhasani, Shiva
    Jalali, Pooya
    Mohammadi, Hamed
    Navashenaq, Jamshid Gholizadeh
    Hojjat-Farsangi, Mohammad
    Jadidi-Niaragh, Farhad
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [18] The molecular biology and therapeutic potential of Nrf2 in leukemia
    Atefeh Khodakarami
    Sara Adibfar
    Vahid Karpisheh
    Shiva Abolhasani
    Pooya Jalali
    Hamed Mohammadi
    Jamshid Gholizadeh Navashenaq
    Mohammad Hojjat-Farsangi
    Farhad Jadidi-Niaragh
    Cancer Cell International, 22
  • [19] Potential Applications of NRF2 Modulators in Cancer Therapy
    Panieri, Emiliano
    Buha, Aleksandra
    Telkoparan-Akillilar, Pelin
    Cevik, Dilek
    Kouretas, Demetrios
    Veskoukis, Aristidis
    Skaperda, Zoi
    Tsatsakis, Aristidis
    Wallace, David
    Suzen, Sibel
    Saso, Luciano
    ANTIOXIDANTS, 2020, 9 (03)
  • [20] Nrf2: a potential therapeutic target for diabetic neuropathy
    Kumar, Anil
    Mittal, Ruchika
    INFLAMMOPHARMACOLOGY, 2017, 25 (04) : 393 - 402